Topics

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 33, Status: Authorised

09:50 EDT 14 Mar 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 33, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 33, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 33, Status: Authorised"

Quick Search

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...